Search & Analyze

Zydus Lifesciences Ltd.

HealthcarePharmaceuticals & Drugs

www.zyduscadila.com BSE: 532321NSE: ZYDUSLIFE

₹1,127.85BSE0.63%

23 Oct, 4:01 PM

₹1,127.85

₹1.13L Cr

24.93

4.17

19.69%

₹1,143.10

₹1,118.95

₹1,232.00

₹835.85

Customise metrics bar

Zydus Lifesciences Ltd. (ZYDUSLIFE) share price closed at ₹1,127.85 on the BSE on Friday, October 23, 2026, down by 0.63% from its of ₹1,135.00. In that session ZYDUSLIFE reached a of 1,143.10 and of 1,118.95. The for the session was 1,126.34. The stands at 1,143.57 and is at 1,025.75. Looking at , the stock ended the session moving sideways.

Stock Overview

Symbol

ZYDUSLIFE

₹1,137.40

₹1,135.00

₹1,126.34

₹1,143.57

Price 1.37% below

₹1,025.75

Price 9.95% above

36.85% of range

₹1,118.95₹1,143.10

73.71% of range

₹835.85₹1,232.00

Price Performance

Peer Comparison

Name
SUN PHARMA. SUNPHARMA	1,743.00	34.58	4,18,204.09	0.92	2,901.23	26.53%	15,299.88	10.46%	19.11
DIVI'S LAB. DIVISLAB	8,984.00	81.54	2,38,496.97	0.33	902.00	65.50%	3,080.00	27.80%	21.51
TORRENT PHAR TORNTPHARM	4,482.00	80.26	1,70,480.87	0.85	534.00	-9.64%	4,979.00	50.79%	19.27
Zydus Lifesciences Ltd. ZYDUSLIFE	1,127.85	24.93	1,12,503.47	0.09	990.20	-34.90%	8,017.00	21.96%	21.39
CIPLA LTD. CIPLA	1,337.00	32.04	1,08,012.30	0.97	785.55	-39.18%	7,119.28	2.33%	16.00
LAURUSLABS LAURUSLABS	1,974.00	97.55	1,06,657.63	0.10	362.07	123.94%	2,026.31	29.10%	18.20
DR.REDDY'S DRREDDY	1,224.50	36.50	1,02,206.60	0.65	913.20	-31.69%	8,697.80	-1.48%	13.75
MANKIND MANKIND	2,217.00	44.83	91,572.10	0.05	574.09	29.12%	4,030.59	12.89%	13.24

Quarterly Results

consolidated figures in ₹ Crores · Quarterly

Particulars	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	5,533.80	6,207.50	5,237.00	5,269.10	6,527.90	6,573.70	6,123.20	6,864.50	7,587.00	8,017.00
Expenses	3,908.60	4,123.50	3,821.00	3,881.50	4,402.40	4,485.20	4,521.50	5,048.10	5,677.50	6,087.60
	1,625.20	2,084.00	1,416.00	1,387.60	2,125.50	2,088.50	1,601.70	1,816.40	1,909.50	1,929.40
	29.37%	33.57%	27.04%	26.33%	32.56%	31.77%	26.16%	26.46%	25.17%	24.07%
	161.70	63.20	113.60	57.50	-139.00	154.90	488.90	26.50	381.60	87.90
Interest	34.60	32.20	25.10	32.00	76.60	84.70	101.30	129.90	123.00	156.00
	205.30	215.30	233.60	229.00	237.90	238.10	301.90	359.60	508.40	554.70
	1,564.10	1,918.60	1,293.00	1,206.00	1,666.90	1,955.00	1,692.60	1,411.20	1,659.40	1,344.40
	20.54%	22.73%	28.86%	14.88%	25.39%	22.20%	26.82%	27.52%	19.19%	26.35%
	1,182.30	1,419.90	911.20	1,023.50	1,170.90	1,466.80	1,258.60	1,042.10	1,272.50	939.80
	11.75	14.11	9.06	10.17	11.64	14.58	12.51	10.36	12.65	9.42

Profit & Loss

consolidated figures in ₹ Crores · Annual

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
INCOME :
	29,555.50	33,911.50	37,929.30	45,680.80	51,679.60
	15,109.90	17,237.40	19,547.40	23,241.50	27,148.40
EXPENDITURE :
Increase/Decrease in Stock	-362.30	238.10	-250.20	-184.90	-887.50
Raw Material Consumed	5,119.30	5,097.60	5,510.30	5,530.30	7,131.50
Power & Fuel Cost	299.30	343.50	366.30	358.20	398.90
Employee Cost	2,177.70	2,456.40	2,789.00	3,289.70	3,978.40
Other Manufacturing Expenses	2,272.30	2,639.80	2,758.10	3,464.70	3,968.80
General and Administration Expenses	506.70	620.30	625.00	933.50	894.50
Selling and Distribution Expenses	1,373.30	1,674.60	1,800.10	2,208.40	3,454.40
Miscellaneous Expenses	548.90	595.20	649.80	748.10	1,019.40
	11,935.20	13,665.50	14,248.40	16,348.00	19,958.40
Operating Profit (Excl OI)	3,174.70	3,571.90	5,299.00	6,893.50	7,190.00
	390.70	474.60	369.40	459.60	1,794.60
	3,565.40	4,046.50	5,668.40	7,353.10	8,984.60
Interest	127.00	129.90	81.20	191.00	438.90
PBDT	3,438.40	3,916.60	5,587.20	7,162.10	8,545.70
	713.00	722.70	764.10	915.80	1,408.00
Profit Before Taxation & Exceptional Items	2,725.40	3,193.90	4,823.10	6,246.30	7,137.70
Exceptional Income / Expenses	112.70	-604.20	-14.20	-219.60	-516.60
	2,838.10	2,589.70	4,808.90	6,026.70	6,621.10
Provision for Tax	511.70	587.80	977.50	1,411.90	1,594.70
	2,326.40	2,001.90	3,831.40	4,614.80	5,026.40
Extra items				0.00	0.00
Minority Interest	-131.00	-131.60	-113.30	-147.10	-83.50
Share of Associate	46.20	94.60	118.40	57.80	97.10
Consolidated Net Profit	4,487.30	1,960.30	3,859.50	4,525.50	5,040.00
Profit Balance B/F	11,384.20	15,495.80	17,189.80	20,369.00	24,561.60
Appropriations	15,871.50	17,456.10	21,049.30	24,894.50	29,601.60
Equity Dividend %	250.00%	600.00%	300.00%	1,100.00%	100.00%
	43.82	19.37	38.36	44.99	50.10
Adjusted EPS	43.82	19.37	38.36	44.99	50.10

Balance Sheet

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
	102.40	101.20	100.60	100.60	100.60
Total Reserves	16,897.20	17,414.60	19,728.90	23,852.50	27,010.80
Reserve excluding Revaluation Reserve	16,897.20	17,414.60	19,728.90	23,852.50	27,010.80
	16,999.60	17,515.80	19,829.50	23,953.10	27,111.40
Minority Interest	2,054.20	2,172.50	2,272.10	2,405.30	2,470.80
Secured Loans					6.50
Unsecured Loans	362.10				3,181.50
Deferred Tax Assets / Liabilities	-942.00	-1,068.00	-1,197.70	-1,831.20	-374.60
Other Long Term Liabilities	61.30	71.20	1,081.10	905.20	1,745.20
Long Term Provisions	325.00	271.80	309.70	383.90	445.30
Total Non-Current Liabilities	-193.60	-725.00	193.10	-542.10	5,003.90
Trade Payables	2,137.80	2,125.00	2,126.70	2,280.70	2,845.10
Other Current Liabilities	1,967.50	1,798.50	1,677.60	2,524.30	7,620.40
Short Term Borrowings	3,314.10	1,081.00	768.60	3,169.50	4,401.60
Short Term Provisions	407.40	522.20	766.80	1,067.10	844.80
Total Current Liabilities	7,826.80	5,526.70	5,339.70	9,041.60	15,711.90
Total Liabilities	26,699.60	24,494.00	27,636.60	34,857.90	50,298.00
Gross Block	17,650.90	18,343.80	19,919.80	21,699.80	34,309.80
Less: Accumulated Depreciation	5,462.40	6,822.90	7,551.30	8,566.10	10,204.00
Net Block	12,188.50	11,520.90	12,368.50	13,133.70	24,105.80
Capital Work in Progress	661.00	1,130.20	1,111.50	1,317.90	1,165.70
Non Current Investments	934.80	927.30	968.00	1,556.70	1,764.10
Long Term Investment	934.80	927.30	968.00	1,556.70	1,764.10
Long Term Loans & Advances	369.30	358.70	344.50	400.10	776.60
Other Non Current Assets	219.70	470.00	30.90	29.40	46.90
Total Non-Current Assets	14,438.20	14,477.60	16,135.20	17,811.80	30,391.90
Currents Investments	2,353.20	619.30	252.50	4,855.50	5,775.80
Inventories	3,719.40	3,413.30	3,441.90	3,944.00	5,628.10
Sundry Debtors	3,340.30	4,416.80	5,220.20	4,084.80	5,415.70
Cash and Bank	1,106.90	573.10	1,105.10	2,956.80	1,416.60
Other Current Assets	229.90	274.00	664.20	500.60	487.70
Short Term Loans and Advances	1,345.50	711.70	735.90	704.40	1,182.20
Total Current Assets	12,095.20	10,008.20	11,419.80	17,046.10	19,906.10
Net Current Assets (Including Current Investments)	4,268.40	4,481.50	6,080.10	8,004.50	4,194.20
Total Assets	26,699.60	24,494.00	27,636.60	34,857.90	50,298.00
Contingent Liabilities	655.60	801.10	753.20	731.80	989.90
Total Debt	4,196.00	1,163.20	768.60	3,169.50	11,769.50
	166.01	173.08	197.11	238.10	269.50
Adjusted Book Value	166.01	173.08	197.11	238.10	269.50

Cash Flow

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
	5,232.30	2,582.70	4,838.10	6,026.70	6,621.10
Adjustment	-2,117.20	933.90	546.70	1,020.40	-289.80
Changes In working Capital	-336.00	-235.80	-902.70	1,535.90	-2,623.70
Cash Flow after changes in Working Capital	2,779.10	3,280.80	4,482.10	8,583.00	3,707.60
Cash Flow from Operating Activities	2,104.50	2,688.80	3,196.30	6,781.10	2,116.60
Cash Flow from Investing Activities	-1,000.30	1,535.00	-1,475.20	-8,357.80	-8,296.10
Cash Flow from Financing Activitie	-868.30	-4,400.40	-1,778.80	1,995.30	5,806.90
Net Cash Inflow / Outflow	235.90	-176.60	-57.70	418.60	-372.60
Opening Cash & Cash Equivalents	888.30	657.80	487.80	413.00	826.80
Cash & Cash Equivalent of Subsidiaries under liquidations	-25.90		6.00	16.60	190.20
Effect of Foreign Exchange Fluctuations	8.60	6.60	-23.10	-21.40	210.80
Closing Cash & Cash Equivalent	1,106.90	487.80	413.00	826.80	855.20

Ratios

Valuation

24.93

4.17

14.00

4.01

45.24

270.31

Profitability

19.69

21.39

11.81

13.91

9.73

Leverage & Liquidity

0.43

1.27

16.09

Returns

0.09

1.21

Shareholding Pattern

Numbers in percentages

Particulars	Jun '24	Sep '24	Dec '24	Mar '25	Jun '25	Sep '25	Dec '25	Mar '26	Jun '26	Sep '26
	74.98	74.98	74.98	74.99	74.99	74.99	75.00	75.00	75.01	75.01
	18.22	18.17	18.18	18.33	18.26	18.20	18.15	18.15	18.15	18.33
	6.79	6.85	6.84	6.68	6.74	6.80	6.85	6.86	6.83	6.66
	25.02	25.02	25.02	25.01	25.01	25.01	25.00	25.00	24.99	24.99
No. of Shareholders	3,36,309	3,70,863	3,65,356	3,71,619	3,86,127	3,96,105	4,03,266	4,18,314	3,99,251	3,82,067

Mutual Funds Invested(212)

Based on each fund's latest monthly portfolio · Sep 2026

A total of 104 active funds hold 6.29% in Zydus Lifesciences Ltd., contributing to ₹7.29K Cr of holdings

Fund				As of
PP Parag Parikh Flexi Cap Fund - Growth - Direct PlanFlexi Cap Fund	2,238.34	1.54	1,92,62,784	Sep '26
KO Kotak Flexi Cap Fund - Growth - Direct PlanFlexi Cap Fund	1,209.83	2.28	1,04,11,615	Sep '26
HS HSBC Midcap Fund - Growth - Direct PlanMid Cap Fund	473.98	2.82	40,78,983	Sep '26
ID Bandhan Large & Mid Cap Fund - Growth - Direct PlanLarge & Mid Cap	343.67	1.66	29,57,548	Sep '26
IP ICICI Prudential Large Cap Fund - Growth - Direct PlanLarge Cap Fund	288.29	0.38	24,81,016	Sep '26
QU Quant Multi Cap Fund - Growth - Direct PlanMulti Cap Fund	274.63	3.66	23,63,448	Sep '26
QU Quant Mid Cap Fund - Growth - Direct PlanMid Cap Fund	239.70	3.13	20,62,800	Sep '26
QU Quant ELSS Tax Saver Fund - Growth - Direct PlanEquity - ELSS - Tax Saver Fund	210.19	1.60	18,08,829	Sep '26
QU Quant Aggressive Hybrid Fund - Growth - Direct PlanHybrid - Aggressive Hybrid Fund	202.74	9.62	17,44,785	Sep '26
QU Quant Flexi Cap Fund - Growth - Direct PlanFlexi Cap Fund	201.25	2.75	17,31,923	Sep '26

Corporate Actions

Showing: All

Date	Type	Details
2026-10-19	Board Meeting	Quarterly Results
2026-07-20	Board Meeting	Quarterly Results
2026-05-27	AGM

Insider Trading

Date	Person	Category	Transaction Type	Shares
2026-08-24	Prashant Babubhai Patel	Others	Buy	32,577
2026-06-20	Arati Rajiv Mehta Joint with Rajiv Vastupal Mehta	Buy Back	Sell	640
2026-06-20	Jigar Mukesh Patel	Buy Back	Sell	73
2026-06-20	Mukesh Mangalbhai Patel	Buy Back	Sell	98
2026-06-20	Pankaj Ramanbhai Patel	Buy Back	Sell	124
2026-06-20	Pankaj Ramanbhai Patel HUF	Buy Back	Sell	248
2026-06-20	Pankaj Ramanbhai Patel Smaller HUF	Buy Back	Sell	124
2026-06-20	Pripan Investment Pvt Ltd	Buy Back	Sell	149
2026-06-20	Pritiben Pankajbhai Patel	Buy Back	Sell	124
2026-06-20	R B Patel Will Pankaj Trust	Buy Back	Sell	109
2026-06-20	Ritaben Yatin Desai	Buy Back	Sell	209
2026-06-20	Sharvil Pankajbhai Patel	Buy Back	Sell	124
2026-06-20	Shivani Patel	Buy Back	Sell	124
2026-06-20	Taraben Patel Family Will Trust	Buy Back	Sell	124
2026-06-20	Tushar Dhansukh Shroff	Buy Back	Sell	5
2026-06-20	Zydus Family Trust	Buy Back	Sell	6,349,542
2026-05-26	Samar Babubhai Patel	Off Market	Buy	10,000

Sector Overview

HealthcarePharmaceuticals & Drugs

Zydus Lifesciences Ltd. operates in the Healthcare sector under the Pharmaceuticals & Drugs industry. This sector is one of the key drivers of the Indian economy and is closely tracked by the relevant Nifty sectoral index.

Company Profile

Corporate information and contact details

Key Management

10 members across the board and senior leadership

Dhaval N Soni

Company Secretary & Compliance Officer

—

Pankaj R Patel

Chairman

₹9.00 L

Mar '26

Bhadresh K Shah

Non Executive Independent Director

₹41.00 L

Mar '26

Shelina P Parikh

Non Executive Independent Woman Director

₹41.00 L

Mar '26

Akhil Monappa

Non Executive Independent Director

₹45.00 L

Mar '26

Upasana Konidela

Non Executive Independent Woman Director

₹35.00 L

Mar '26

Kulin S Lalbhai

Non Executive Independent Director

—

Sharvil P Patel

Managing Director

₹45.00 Cr

Mar '26

Mukesh M Patel

Non Independent & Non Executive Director

₹40.00 L

Mar '26

Ganesh N Nayak

Non Executive Director

₹4.60 Cr

Mar '26

ZYDUSLIFE Latest News

News

10 of 10 articles

EQUITY22 Oct 2026 · 11:35

Zydus Lifesciences rises as its arm partners with Prolific Machines

Zylidac will first complete a tech transfer of Prolific's process at 50- liter scale to reproduce Prolific's results at the Zylidac site

COMPANY22 Oct 2026 · 11:27

Zydus Lifesciences’ arm partners with Prolific Machines

Zylidac will first complete a tech transfer of Prolific's process at 50- liter scale to reproduce Prolific's results at the Zylidac site

COMPANY21 Oct 2026 · 15:30

Zydus Lifesciences gets USFDA’s final nod for Estradiol and Levonorgestrel Transdermal System

Estradiol and Levonorgestrel Transdermal System is primarily used treat moderate to severe symptoms of menopause

EQUITY21 Oct 2026 · 14:40

Zydus Lifesciences informs about press release

EQUITY19 Oct 2026 · 17:49

Zydus Lifesciences submits board meeting intimation

EQUITY15 Oct 2026 · 12:50

Zydus Life surges as its JV inks pact to set up pharmaceutical manufacturing facility in Sri Lanka

Zydus Sunshine Lifesciences has inked an agreement with the Board of Investment of Sri Lanka

COMPANY15 Oct 2026 · 12:42

Zydus Lifesciences’ JV to set up pharmaceutical manufacturing facility in Sri Lanka

Zydus Sunshine Lifesciences has inked an agreement with the Board of Investment of Sri Lanka

COMPANY14 Oct 2026 · 10:12

USFDA concludes inspection of Zydus Lifesciences’ Ahmedabad plant with 5 observations

The inspection was conducted from October 5, 2026 to October 13, 2026

EQUITY13 Oct 2026 · 11:12

Zydus Lifesciences informs about press release

EQUITY6 Oct 2026 · 09:28

Zydus Lifesciences rises on launching Riociguat Tablets in US in partnership with MSN Laboratories

The product was developed and is manufactured by MSN

ZYDUSLIFE

₹1,127.85

-0.63%